Translational paradigms in pharmacology and drug discovery

Biochemical Pharmacology

Volumn 87, Issue 1, 2014, Pages 189-210

  Mullane, Kevin ^a   Winquist, Raymond J ^b   Williams, Michael ^c  

^a Profectus Pharma Consulting   (United States)

^b VERTEX PHARMACEUTICALS   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Bias; Biomarkers; Drug discovery; Pharmacology; Translational science

Indexed keywords

ALTEPLASE; ANTIBIOTIC AGENT; ANTICOAGULANT AGENT; ATORVASTATIN; BENALFOCIN; BIOLOGICAL MARKER; CANGRELOR; CLOPIDOGREL; DISUFENTON SODIUM; ELINOGREL; EPIGALLOCATECHIN GALLATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPERICUM PERFORATUM EXTRACT; IMMUNOGLOBULIN G ANTIBODY; MESSENGER RNA; MORPHINE; NATURAL PRODUCT; PACLITAXEL; PLANT MEDICINAL PRODUCT; PRASUGREL; RNA; ROMIDEPSIN; SABAL EXTRACT; SIMVASTATIN; STAUROSPORINE; TACROLIMUS; TICAGRELOR; UNINDEXED DRUG; VALPROIC ACID; VORINOSTAT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ALGORITHM; ALZHEIMER DISEASE; APOPTOSIS; AUTOIMMUNE DISEASE; BIOTECHNOLOGY; CEREBROVASCULAR ACCIDENT; COMPUTER SYSTEM; CONCEPTUAL FRAMEWORK; DRUG DESIGN; DRUG METABOLISM; DRUG SCREENING; EPIGENETICS; GENE IDENTIFICATION; GENE THERAPY; GENETIC ASSOCIATION; GENOTYPE; GENOTYPE ENVIRONMENT INTERACTION; HERITABILITY; HIGH THROUGHPUT SEQUENCING; HUMAN; HYPERICUM PERFORATUM; MEDICAL RESEARCH; MEDICINE; MEDLINE; MICROCOMPUTER; MOLECULAR BIOLOGY; MOLECULAR RECOGNITION; NEXT GENERATION SEQUENCING; NONHUMAN; PEER REVIEW; PHARMACOGENOMICS; PHARMACOLOGY; PHARMACOPHORE; PHENOTYPE; PLURIPOTENT STEM CELL; PREDICTIVE VALUE; PRIORITY JOURNAL; PUBLISHING; REVIEW; RNA SEQUENCE; SABAL; SCIENTIST; SCORING SYSTEM; SEQUENCE ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; STATISTICAL ANALYSIS; TRAINING; TRANSLATIONAL RESEARCH;

BIAS; BIOMARKERS; DRUG DISCOVERY; PHARMACOLOGY; TRANSLATIONAL SCIENCE;

ANIMALS; BIOMEDICAL RESEARCH; DRUG DISCOVERY; DRUG EVALUATION, PRECLINICAL; HUMANS; PHARMACOLOGY; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84892365294     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2013.10.019     Document Type: Review

References (298)

1. H. Moses III, and J.B. Martin Biomedical research and health advances N Engl J Med 364 2011 567 571
2. D.F. Horrobin Modern biomedical research: an internally self-consistent universe with little contact with medical reality? Nat Rev Drug Discov 2 2003 151 154 (Pubitemid 37361647)
3. N.S. Sung, W.F. Crowley Jr., M. Genel, P. Salber, L. Sandy, and L.M. Sherwood et al. Central challenges facing the national clinical research enterprise J Am Med Assoc 289 2003 1278 1287 (Pubitemid 37432909)
4. S.H. Woolf The meaning of translational research and why it matters J Am Med Assoc 299 2008 211 213
5. M. Helfand, S. Tunis, E.P. Whitlock, S.G. Pauker, A. Basu, and J. Chilingerian et al. A CTSA agenda to advance methods for comparative effectiveness research Clin Transl Sci 4 2011 188 198
6. P. Morgan, P.H. Van Der Graaf, J. Arrowsmith, D.E. Feltner, K.S. Drummond, and C.D. Wegner et al. Can the flow of medicines be improved? Fundamental pharmacokinetic and pharmacological principles toward improving Phase II survival Drug Discov Today 17 2012 419 424
7. ASPET Division for Integrative Systems. Translational and clinical pharmacology mission statement. http://www.aspet.org/ISTCP/Home/ [accessed 11.09.13].
8. R.J. Winquist, K.M. Mullane, and M. Williams The fall and rise of pharmacology - (re-) defining the discipline? Biochem Pharmacol 87 2014 4 24
9. E.R. Dorsey, J.P. Thompson, M. Carrasco, J. de Roulet, P. Vitticore, and S. Nicholson et al. Financing of U.S. Biomedical Research and New drug approvals across therapeutic areas PLoS ONE 4 2009 e7015
10. P.D. Leeson, and B. Springthorpe The influence of drug-like concepts on decision-making in medicinal chemistry Nat Rev Drug Discov 6 2007 881 890 (Pubitemid 350042396)
11. X. Sun, S. Vilar, and N.P. Tatonetti High-throughput methods for combinatorial drug discovery Sci Transl Med 5 2013 205rv1
12. Y.L. Bennani Drug discovery in the next decade: innovation needed ASAP Drug Discov Today 16/17 2012 779 792
13. P. Imming, C. Sinning, and A. Meyer Drugs, their targets and the nature and number of drug targets Nat Rev Drug Discov 5 2006 821 834 (Pubitemid 44480536)
14. D.C. Swinney, and J. Anthony How were new medicines discovered? Nat Rev Drug Discov 10 2011 507 519
15. D.C. Swinney Phenotypic vs. target-based drug discovery for first-in-class medicines Clin Pharmacol Ther 93 2013 299 301
16. M. Schenone, V. Dančík, B.K. Wagner, and P.A. Clemons Target identification and mechanism of action in chemical biology and drug discovery Nat Chem Biol 9 2013 232 240
17. D.C. Anderson, and K. Kodulka Biomarkers in pharmacology Biochem Pharmacol 87 2014 172 188
18. G.M. Simon, M.J. Niphakis, and B.F. Cravatt Determining target engagement in living systems Nat Chem Biol 9 2013 200 205
19. S.A.G. Visser, M. Aurell, R.D.O. Jones, V.J.A. Schuck, A.-C. Egnell, and A. Sheila et al. Model-based drug discovery: implementation and impact Drug Discov Today 18 2013 764 775
20. P. McGonigle, and B. Ruggeri Animal models of human disease: Challenges in enabling translation Biochem Pharm 87 2014 162 171
21. J. Fan, and I.A.M. de Lannoy Pharmacokinetics in pharmacology Biochem Pharmacol 87 2014 93 120
22. Kl. Steinmetz, and E.G. Spack The basics of preclinical drug development for neurodegenerative disease indications BMC Neurol 9 Suppl. 1 2009 S2
23. L. Ewart, D.J. Gallacher, G. Gintant, J.-M. Guillon, D. Leishman, and P. Levesque et al. How do the top 12 pharmaceutical companies operate safety pharmacology? J Pharmacol Toxicol Methods 66 2012 66 70
24. M.N. Liebman, and F.M. Marincola Expanding the perspective of translational medicine: the value of observational data J Transl Med 10 2012 61
25. J.P. Hughes, S. Rees, S.B. Kalindjian, and K.L. Philpott Principles of early drug discovery Br J Pharmacol 162 2011 1239 1249
26. P. Cooke Regional innovation systems: general findings and some new evidence from biotechnology clusters J Technol Transfer 27 2002 133 145
27. P. Benneworth, and G.-J. Hospers The new economic geography of old industrial regions: universities as global-local pipelines Environ Plann C: Govern Policy 25 2007 779 802
28. M. Feldman, and E. Romanelli Organizational legacy and the internal dynamics of clusters: the U.S. Human Biotherapeutics Industry, 1976-2002 P. Meusburger, J. Glückler, M. el Meskioui, Knowledge and space vol. 5 2013 Springer Science + Business Media Dordrecht, Germany 207 230
29. Elkind P, Reingold J, Burke D. Inside Pfizer's palace coup. Fortune; 2011. http://features.blogs.fortune.cnn.com/2011/07/28/pfizer-jeff-kindler- shakeup/.
30. H. Hörig, and W. Pullman From bench to clinic and back: perspective on the 1st IQPC Translational Research conference J Transl Med 2 2004 44
31. Menand L. The marketplace of ideas. Forbes; 2009. http://Forbes.com/2009/ 08/02/university-education-reform-opinions-colleges-09-louis-menand.html.
32. M. Crichton quoted in Loscalzo J. Experimental irreproducibility: causes, (mis)interpretations, and consequences Circulation 125 2012 1211 1214
33. T. Kenakin, D.B. Bylund, M.L. Toews, M. Mullane, R.J. Winquist, and M. Williams Replicated, replicable and relevant - target engagement and pharmacological experimentation in the 21st Century Biochem Pharmacol 87 2014 64 77
34. J.P.A. Ioannidis Why most published research findings are false PLoS Med 2005 e124
35. F. Prinz, T. Schlange, and K. Asadullah Believe it or not: how much can we rely on published data on potential drug targets? Nat Rev Drug Discov 10 2011 712 713
36. C.G. Begley, and L.M. Ellis Drug development: raise standards for preclinical cancer research Nature 483 2012 531 533
37. J. Loscalzo Experimental irreproducibility: causes, (mis)interpretations, and consequences Circulation 125 2012 1211 1214
38. D. Fanelli How many scientists fabricate and falsify research? A systematic review and meta-analysis of survey data PLoS ONE 4 2009 e5738
39. Freedman DH. Lies, damned lies, and medical science. The Atlantic; 2010. http://www.theatlantic.com/magazine/archive/2010/11/lies-damned-lies-and- medical-science/308269/.
40. P. Kakuk The legacy of the hwang case: research misconduct in biosciences Sci Engineer Ethics 1 2009 645 662
41. F.C. Fang, G.R. Steen, and A. Casadevall Misconduct accounts for the majority of retracted scientific publications Proc Natl Acad Sci USA 109 2012 17028 17033
42. Bhattacharjee Y. The mind of a con man, new york times magazine; 2013. http://www.nytimes.com/2013/04/28/magazine/diederik-stapels-audacious-academic- fraud.html?pagewanted=all&-r=1&.
43. R.G. Steen Retractions in the scientific literature: is the incidence of research fraud increasing? J Med Ethics 37 2011 249 253
44. R.G. Steen, A. Casadevall, and F.C. Fang Why has the number of scientific retractions increased? PLoS ONE 8 2013 e68397
45. J.P.A. Ioannidis Why science is not necessarily self-correcting Perspect Psychol Sci 7 2012 645 654
46. M. Rosenblatt How academia and the pharmaceutical industry can work together Ann Am Thorac Soc 10 2013 31 38
47. Borrel B. A medical Madoff: anesthesiologist faked data in 21 studies. Sci Am; 2009. http://www.scientificamerican.com/article.cfm?id=a-medical-madoff- anesthestesiologist-faked-data.
48. B. Deer How the case against the MMR vaccine was fixed Br Med J 342 2011 c5347
49. F. Godlee, J. Smith, and H. Marcovitch Wakefield's article linking MMR vaccine and autism was fraudulent Br Med J 342 2011 c7452
50. Y. Lazebnik Can a biologist fix a radio? Or, what I learned while studying apoptosis Cancer Cell 2 2002 179 182 (Pubitemid 41043973)
51. S. Brenner An interview with. Sydney Brenner, Interview by Errol C. Friedberg Nat Rev Mol Cell Biol 9 2008 8 9
52. H. Kubinyi Drug research: myths, hype and reality Nat Rev Drug Discov 2 2003 665 668 (Pubitemid 37368830)
53. D. Shaywitz, and N. Taleb Drug research needs serendipity. Financial Times 2008 [ http://www.ft.com/intl/cms/s/0/b735787c-5d9b-11dd-8129- 000077b07658.html
54. L. Muchnik, S. Aral, and S.J. Taylor Social influence bias: a randomized experiment Science 341 2013 647 651
55. FDA Innovation or stagnation Challenge and opportunity on the critical path to new medical products 2004 FDA Bethesda, MD [ http://www.fda.gov/oc/ initiatives/criticalpath/whitepaper.html [accessed October 2013]
56. B. Munos Lessons from 60 years of pharmaceutical innovation Nat Rev Drug Discov 8 2009 959 968
57. F. Pammolli, L. Magazzini, and M. Riccaboni The productivity crisis in pharmaceutical R & D Nat Rev Drug Discov 10 2011 428 438
58. D.W. Light, and R. Warburton Demythologizing the high costs of pharmaceutical research BioSocieties 6 2011 34 50
59. J. Mestre-Ferrandiz, J. Sussex, and A. Towse The R & D cost of a new medicine 2012 Office of Health Economics London, UK
60. M. Herper The cost of creating a new drug now $5 billion, pushing big pharma to change. Forbes 2013 [ http://www.forbes.com/sites/matthewherper/ 2013/08/11/how-the-staggering-cost-of-inventing-new-drugs-is-shaping-the-future- of-medicine/
61. J.W. Scannell, A. Blanckley, H. Boldon, and B. Warrington Diagnosing the decline in pharmaceutical R&D efficiency Nat Rev Drug Discov 11 2012 191 200
62. M. Williams Productivity shortfalls in drug discovery: contributions from the preclinical sciences? J Pharmacol Exp Ther 336 2011 3 8
63. D.L. Sackett Bias in analytic research J Chronic Dis 32 1979 51 63
64. J. Lehrer The science of irrationality. Wall street J 2011 [ http://online.wsj.com/article/SB10001424052970203633104576625071820638808.html
65. A. Mandavilli Peer review: trial by twitter Nature 469 2011 286 287
66. M. Rossner, and K.M. Yamada What's in a picture? The temptation of image manipulation" J Cell Biol 166 2004 11 15
67. M. Rossner How to guard against image fraud. The scientist 2006 [ http://www.the-scientist.com/?articles.view/articleNo/23749/title/ How-to-Guard-Against-Image-Fraud/
68. D.B. Bylund, and M. Toews Quantitative versus qualitative data - the numerical dimension in biomedical research Biochem Pharmacol 87 2014 25 39
69. M. Kitazawa Circadian rhythms, metabolism, and insulin sensitivity: transcriptional networks in animal models Curr Diabetes Reports 13 2013 223 228
70. M.C. Antle, and R. Silver Orchestrating time: arrangements of the brain circadian clock Trends Neurosci 28 2005 145 151 (Pubitemid 40320760)
71. M. Hastings, J.S. O'Neill, and E.S. Maywood Circadian clocks: regulators of endocrine and metabolic rhythms J Endocrinol 195 2007 187 198 (Pubitemid 350143100)
72. F.G. Revel, J. Gottowik, S. Gatti, J.G. Wettstein, and J.-L. Moreau Rodent models of insomnia: a review of experimental procedures that induce sleep disturbance Neurosci Biobehavior Rev 33 2009 874 899
73. F. Levi, and U. Schibler Circadian rhythms: mechanisms and therapeutic implications Ann Rev Pharmacol Toxicol 47 2007 593 628
74. R.L. Sack, D. Auckley, R.R. Auger, M.A. Carskadon, K.P. Wright Jr., and M.V. Vitiello et al. Circadian rhythm sleep disorders: Part I, basic principles, shift work and jet lag disorders: an American Academy of Sleep Medicine review Sleep 30 2007 1460 1483 (Pubitemid 350036973)
75. G.S. Malhi, and S. Kuiper Chronobiology of mood disorders Acta Psychiatr Scand 128 s444 2013 2 15
76. F. Lévi, A. Altinok, J. Clairambault, and A. Goldbeter Implications of circadian clocks for the rhythmic delivery of cancer therapeutics Philos Trans A: Math Phys Eng Sci 366 2008 3575 3598
77. S.N. Farrow, R. Solari, and T.M. Willson The importance of chronobiology to drug discovery Exp Opin Drug Discov 7 2012 535 541
78. L.A. Toth, and P. Bhargava Animal models of sleep disorders Comp Med 63 2013 91 104
79. W. Huang, K.M. Ramsey, B. Marcheva, and J. Bass Circadian rhythms, sleep, and metabolism J Clin Invest 121 2011 2133 2141
80. T. Kenakin, and M. Williams Defining and characterizing drug/compound function Biochem Pharmacol 87 2014 40 63
81. J.H. McDonald Handbook of biological statistics 2nd ed. 2009 Sparky House Publishing Baltimore, MD 15 20 [ http://www.lulu.com/product/18578349
82. V. Bebarta, D. Luyten, and K. Heard Emergency medicine animal research: does use of randomization and blinding affect the results? Acad Emerg Med 10 2003 684 687 (Pubitemid 36667073)
83. E.S. Sean, H.B. van der Worp, P.M.W. Bath, D.W. Howells, and M.R. Macleod Publication bias in reports of animal stroke studies leads to major overstatement of efficacy PLoS Biol 8 2010 e1000344
84. M. Marino The use and misuse of statistical methodologies in pharmacology research Biochem Pharmacol 87 2014 78 92
85. K.S. Button, J.P. Ioannidis, C. Mokrysz, B.A. Nosek, J. Flint, and E.S. Robinson et al. Power failure: why small sample size undermines the reliability of neuroscience Nat Rev Neurosci 14 2013 365 376
86. V.C. Henderson, J. Kimmelman, D. Fergusson, J.M. Grimshaw, and D.G. Hackam Threats to validity in the design and conduct of preclinical efficacy studies: a systematic review of guidelines for in vivo animal experiments PLoS Med 2013 e1001489
87. C. Kilkenny, N. Parsons, E. Kadyszewski, M.F.W. Festing, and I.C. Cuthill et al. Survey of the quality of experimental design, statistical analysis and reporting of research using animals PLoS ONE 4 2009 e7824
88. M. Wadman NIH mulls rules for validating key results Nature 500 2013 14 16
89. F.S. Collins, E.D. Green, A.E. Guttmacher, and M.S. Guyer US National Human Genome Research Institute. a vision for the future of genomics research Nature 422 2003 835 847 (Pubitemid 36520032)
90. F.S. Collins Has the revolution arrived? Nature 464 2010 674 675
91. K. Mullane, and M. Williams Translational semantics and infrastructure: another search for the Emperor's clothes Drug Discov Today 17 2012 459 468
92. D. Lowe Sloppy science. In The Pipeline http://pipeline.corante.com/ archives/2012/03/29/sloppy-science.php
93. M.B. Buntin, M.F. Burke, M.C. Hoaglin, and D. Blumenthal The benefits of health information technology: a review of the recent literature shows predominantly positive results Health Affair 30 2011 3464 3471
94. K.K. Tsilidis, O.A. Panagiotou, E.S. Sena, E. Aretouli, E. Evangelou, and D.W. Howells et al. Evaluation of excess significance bias in animal studies of neurological diseases PLoS Biol 11 2013 e1001609
95. J.P.A. Ioannidis, and T.A. Trikalinos Early extreme contradictory estimates may appear in published research: the Proteus phenomenon in molecular genetics research and randomized trials J Clin Epidemiol 58 2005 543 549 (Pubitemid 40692719)
96. T. Pfeiffer, L. Bertram, and J.P.A. Ioannidis Quantifying selective reporting and the Proteus phenomenon for multiple datasets with similar bias PLoS ONE 6 2011 e18362
97. J.P. Ioannidis Excess significance bias in the literature on brain volume abnormalities Arch Gen Psychiatry 68 2011 773 780
98. A. Mobley, S.K. Linder, R. Braeuer, L.M. Ellis, and L. Zwelling A survey on data reproducibility in cancer research provides insights into our limited ability to translate findings from the laboratory to the clinic PLoS ONE 8 2013 e63221
99. Editorial. Science Publishing: how to stop plagiarism. Nature 2012; 481:21-3.
100. B.R. Martin Whither research integrity? Plagiarism, self-plagiarism and coercive citation in an age of research assessment Res Policy 42 2013 1005 1014
101. Stemwedel JD. The continuum between outright fraud and "sloppy science": inside the frauds of Diederik Stapel (part 5). Sci Am; 2013. http://blogs.scientificamerican.com/doing-good-science/2013/06/26/ the-continuum-between-outright-fraud-and-sloppy-science-inside-the-frauds-of- diederik-stapel-part-5.
102. K.A. Baggerly, and K.R. Coombes Deriving chemosensitivity from cell lines: forensic bioinformatics and reproducible research in high-throughput biology Ann Appl Stat 3 2009 1309 1334
103. J. Couzin-Frankel As questions grow, Duke halts trials, launches investigation Science 329 2010 614 615
104. Retraction Watch, The importance of being reproducible: Keith Baggerly tells the Anil Potti story, Retraction Watch; 2011. http://retractionwatch. wordpress.com/2011/05/04/the-importance-of-being-reproducible-keith-baggerly- tells-the-anil-potti-story/.
105. D. Lowe New frontiers in analytical chemistry. In the pipeline 2013 http://pipeline.corante.com/archives/2013/08/07/new-frontiers-in-analytical- chemistry.php
106. A. Smith III Data integrity Org Lett 15 2013 2893 2894
107. B. Goldacre Bad medicine 2012 Fourth Estate London 1 99
108. D. Eyding, M. Lelgemann, U. Grouven, M. Harter, M. Kromp, and T. Kaiser et al. Reboxetine for acute treatment of major depression: systematic review and meta-analysis of published and unpublished placebo and selective serotonin reuptake inhibitor controlled trials Br Med J 341 2010 4737
109. P. Doshi, K. Dickersin, D. Healy, S.W. Vedula, and T. Jefferson Restoring invisible and abandoned trials: a call for people to publish the findings Br Med J 346 2013 f2865
110. K. Mullane, and M. Williams Alzheimer's therapeutics: continued clinical failures question the validity of the amyloid hypothesis - but what lies beyond? Biochem Pharmacol 85 2013 289 305
111. G. Naik Mistakes in scientific studies surge. Wall St J 2011 [ http://online.wsj.com/article/SB10001424052702303627104576411850666582080.html
112. Begley S. In cancer science, many "discoveries" don't hold up. Reuters; 2012. http://www.reuters.com/article/2012/03/28/us-science-cancer- idUSBRE82R12P20120328.
113. Accenture and CMR International. Rethinking innovation in pharmaceutical R&D; 2005. http://www.accenture.com/Microsites/rdtransformation/Documents/ PDFs/Accenture-Rethinking-Innovation-in-Pharmaceutical.pdf.
114. Horton R. quoted in Naik G. Mistakes in scientific studies surge. Wall St J; 2011. http://online.wsj.com/article/ SB10001424052702303627104576411850666582080.html.
115. C.J. Lee, C.R. Sugimoto, G. Zhang, and B. Cronin Bias in peer review J Am Soc Inform Sci Technol 64 2013 2 17
116. Editorial Reducing our irreproducibility Nature 496 2013 398
117. E.H. Boakes, P.J.K. McGowan, R.A. Fuller, D. Chang-qing, and N.E. Clark et al. Distorted views of biodiversity: spatial and temporal bias in species occurrence data PLoS Biol 8 2010 e1000385
118. T. Greenhalgh How to read a paper 4th ed. 2010 Wiley Blackwell BMJ Books Chichester, UK
119. Columbia Accident Investigation Board. Washington, DC: NASA; 2003. http://spaceflight.nasa.gov/shuttle/archives/sts-107/investigation/ CAIB-medres-full.pdf.
120. E. Tufte PowerPoint does rocket science: assessing the quality and credibility of technical reports, in beautiful evidence 2006 Graphics Press Cheshire, CT 162 170
121. Crippen DL, Daniel CC, Donahue AK, Helms SJ, Livingstone M, O'Leary R et al. NASA return to flight task group final report: Annex A.2 individual member observations; 2005. http://www.spaceref.com/news/viewsr.html?pid=17773.
122. S.M. Bagshaw, M. Zappitelli, and L.S. Chawla Novel biomarkers of AKI: the challenges of progress 'Amid the noise and the haste' Nephrol Dial Transplant 28 2013 235 238
123. J. Schmutz, J. Wheeler, J. Grimwood, M. Dickson, J. Yang, and C. Caoile et al. Quality assessment of the human genome sequence Nature 429 2004 365 368 (Pubitemid 38715122)
124. J.P.A. Ioannidis This I believe in genetics: discovery can be a nuisance, replication is science, implementation matters Front Genet 2013 10.3389/fgene.2013.00033
125. R.J. Klein, C. Zeiss, E.Y. Chew, J.Y. Tsai, R.S. Sackler, and C. Haynes et al. Complement factor H polymorphism in age-related macular degeneration Science 308 2005 385 389 (Pubitemid 40530070)
126. J.J. McCarthy, H.L. McLeod, and G.S. Ginsburg Genomic medicine: a decade of successes, challenges and opportunities Sci Transl Med 5 2013 189sr4
127. International HapMap Consortium The international HapMap project Nature 426 2003 789 796
128. J.P.A. Ioannidis An epidemic of false claims. Competition and conflicts of interest distort too many medical findings Sci Am 304 2011 16
129. J. Di Iulio, and M. Rotger Pharmacogenomics: what is next? Front Pharmacol 2012 10.3389/fphar.20111.00086
130. The ENCODE Project Consortium An integrated encyclopedia of DNA elements in the human genome Nature 489 2012 57 74
131. M.T. Maurano, R. Humbert, E. Rynes, R.E. Thurman, E. Haugen, and H. Wang et al. Systematic localization of common disease-associated variation in regulatory DNA Science 337 2012 1190 1195
132. M. Esteller Non-coding RNAs in human disease Nat Rev Genet 12 2011 861 874
133. T.A. Manolio Bringing genome-wide association findings into clinical use Nat Rev Genet 14 2013 549 558
134. L.R. Brunham, and M.R. Hayden Hunting human disease genes: lessons from the past, challenges for the future Hum Genet 132 2013 603 617
135. P. Marjoram, A. Zubair, and S.V. Nuzhdin Post-GWAS: where next? More samples, more SNPs or more biology? Heredity 2013 10.1038/hdy.2013.52
136. E.S. Lander Initial impact of the sequencing of the human genome Nature 470 2011 187 197
137. N. Zaitlen, P. Kraft, N. Patterson, B. Pasaniuc, G. Bhatia, and S. Pollack et al. Using extended genealogy to estimate components of heritability for 23 quantitative and dichotomous traits PLoS Genet 9 2013 e1003520
138. O. Zuk, E. Hechter, S.R. Sunyaev, and E.S. Lander The mystery of phantom heritability: genetic interactions create phantom heritability Proc Natl Acad Sci USA 109 2012 1193 1198
139. H.H. Hobbs, E. Leitersdorf, C.C. Leffert, D.R. Cryer, M.S. Brown, and J.L. Goldstein Evidence for a dominant gene that suppresses hypercholesterolemia in a family with defective low density lipoprotein receptors J Clin Invest 84 1989 656 664 (Pubitemid 19197001)
140. J.-H. Mao, E.F. Saunier, J.P. de Koning, M.M. McKinnon, M.N. Higgins, and K. Nicklas et al. Genetic variants of Tgfb1 act as a context-dependent modifiers of mouse skin tumor susceptibility Proc Natl Acad Sci USA 103 2006 8125 8130 (Pubitemid 43801063)
141. J. Freimuth, F.F. Clermont, X. Huang, A. DeSapio, T.A. Tokuyasu, and D. Sheppard et al. Epistatic interactions between Tgfb1 and genetic loci, Tgfbm2 and Tgfbm3, determine susceptibility to an asthmatic stimulus Proc Natl Acad Sci USA 109 2012 18042 18047
142. J.F. Gusella, N.S. Wexler, P.M. Conneally, S.L. Naylor, M.A. Anderson, and R.E. Tanzi et al. A polymorphic DNA marker genetically linked to Huntington's disease Nature 306 1983 234 238 (Pubitemid 14232350)
143. M.E. MacDonald, C.M. Ambrose, M.P. Duyao, R.H. Myers, C. Lin, and L. Srinidhin et al. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes Cell 72 1993 971 983 (Pubitemid 23110238)
144. C. Zuccato, M. Valenza, and C. Cattaneo Molecular mechanisms and potential therapeutical targets in Huntington's disease Physiol Rev 90 2010 905 981
145. Moffatt MF, Kabesch M, Liang L, Dixon AL, Strachan D, and Heath S et al. Genetic variants regulating ORMDL3 expression contribute to the risk of childhood asthma Nature 448 2007 470 473 (Pubitemid 47123521)
146. Y. Zhang, M.F. Moffatt, and W.O.C. Cookson Genetic and genomic approaches to asthma: new insights for the origins Curr Opin Pulm Med 18 2012 6 13
147. J.P.A. Ioannidis Genetic prediction for common diseases: will personal genomics ever work? Arch Intern Med 172 2012 744 746
148. C.B. Do, D.A. Hinds, U. Francke, and N. Eriksson Comparison of family history and SNPs for predicting risk of complex disease PLoS Genet 8 2012 e1002973
149. J.G. Smith, C. Newton-Cheh, P. Almgren, O. Melander, and P.G. Platonov Genetic polymorphisms for estimating risk of atrial fibrillation in the general population: a prospective study Arch Intern Med 172 2012 742 744
150. J.A. Tennessen, A.W. Bigham, T.D. O'Connor, W. Fu, E.E. Kenny, and S. Gravel et al. Evolution and functional impact of rare coding variation from deep sequencing of human exomes Science 337 2012 64 69
151. K. Bettens, K. Sleegers, and C. Van Broeckhoven Genetic insights in Alzheimer's disease Lancet Neurol 12 2013 92 104
152. E. Ciarlo, S. Massone, I. Penna, M. Nizzari, A. Gigoni, and G. Dieci et al. An intronic ncRNA-dependent regulation of SORL1 expression affecting Aβ formation is upregulated in post-mortem Alzheimer's disease brain samples Dis Model Mech 6 2013 424 433
153. D.B. Goldstein, A. Allen, J. Keebler, E.H. Margulies, S. Petrou, and S. Petrovski et al. Sequencing studies in human genetics: design and interpretation Nat Rev Genet 14 2013 460 470
154. J. Rung, and A. Brazma Reuse of public genome-wide gene expression data Nat Rev Genet 14 2013 89 99
155. M. Williams Commentary: genome-based CNS drug discovery: d-amino acid oxidase (DAAO) as a novel target for antipsychotic medications: progress and challenges Biochem Pharmacol 78 2009 1360 1365
156. G.S. Firestein, and D.S. Pisetsky DNA microarrays: boundless technology or bound by technology? Guidelines for studies using microarray technology Arthritis Rheum 46 2002 859 861 (Pubitemid 34303795)
157. J.P. Ioannidis, D.B. Allison, C.A. Ball, I. Coulibaly, and X. Cui et al. Repeatability of published microarray gene expression analyses Nat Genet 41 2009 149 155
158. C.J. Bell, D.L. Dinwiddie, N.A. Miller, S.L. Hateley, E.E. Ganusova, and J. Mudge et al. Carrier testing for severe childhood recessive diseases by next-generation sequencing Sci Transl Med 3 2011 65ra4
159. E.R. Mardis Next-generation sequencing platforms Ann Rev Anal Chem 6 2013 287 303
160. V. Marx The genome jigsaw Nature 501 2013 263 268
161. J.R. Lupski Genome mosaicism - one human, multiple genomes Science 341 2013 358 359
162. M. O'Huallachain, K.J. Karczewski, S.M. Weissman, A.W. Urban, and M.P. Snyder Extensive genetic variation in somatic human tissues Proc Natl Acad Sci USA 109 2012 18018 18023
163. F. Ozsolak, and P.M. Milos RNA sequencing: advances, challenges and opportunities Nat Rev Genet 12 2011 87 98
164. K. Kapelli, and G.W. Yeo Genome-wide approaches to dissect the roles of RNA binding proteins in translational control: implications for neurological diseases Front Neurosci 6 2012 144
165. S.E. Ugras, and J. Shorter RNA-binding proteins in amyotrophic lateral sclerosis and neurodegeneration Neurol Res Int 2012 2012 432780
166. M. Polymenidou, C. Lagier-Tourenne, K.R. Hutt, S.C. Huelga, J. Moran, and T.Y. Liang et al. Long pre-mRNA depletion and RNA missplicing contribute to neuronal vulnerability from loss of TDP-43 Nat Neurosci 14 2011 459 468
167. C. Richard-Miceli, and L.A. Criswell Emerging patterns of genetic overlap across autoimmune disorders Genome Med 4 2012 6
168. M. Parkes, A. Cortes, D.A. van Heel, and M.A. Brown Genetic insights into common pathways and complex relationships among immune-mediated diseases Nat Rev Genet 14 2013 661 673
169. X. Li, E.J. Ampleford, T.D. Howard, W.C. Moore, D.G. Torgerson, and H. Li et al. Genome-wide association studies of asthma indicate opposite immunopathogenesis direction from autoimmune diseases J Allergy Clin Immunol 130 2012 861 868
170. W. Hueber, B.E. Sands, S. Lewitzky, M. Vandemeulebroecke, W. Reinisch, and P.D.R. Higgins et al. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomized, double-blind placebo-controlled trial Gut 61 2012 1693 1770
171. A.P. Gregory, C.A. Dendrou, K.E. Attfield, A. Haghikia, D.K. Xifara, and F. Butter et al. TNF receptor 1 genetic risk mirrors outcome of anti-TNF therapy in multiple sclerosis Nature 488 2012 508 511
172. G. Egger, G. Liang, A. Aparicio, and P.A. Jones Epigenetics in human disease and prospects for epigenetic therapy Nature 429 2004 457 463 (Pubitemid 38715140)
173. R. Feil, and M.F. Fraga Epigenetics and the environment: emerging patterns and implications Nat Rev Genet 13 2012 97 109
174. N.T. Ventham, N.A. Kenndey, E.R. Nimmo, and J. Satsangi Beyond gene discovery in inflammatory bowel disease: the emerging role of epigenetics Gastroenterology 145 2013 293 306
175. E.L. Messias, C.-Y. Chen, and W.W. Eaton Epidemiology of schizophrenia: review of findings and myths Psychiatr Clin N Am 30 2007 323 338 (Pubitemid 47299146)
176. J.D. Duarte Epigenetics primer: why the clinician should care about epigenetics Pharmacotherapy 2013 10.1002/phar.1325
177. D. Weichenhan, and C. Plass The evolving epigenome Hum Mol Genet 2013 10.1093/hmg/ddt348
178. E. Dirkx, P.A. da Costa Martins, and L.J. De Windt Regulation of fetal gene expression in heart failure Biochim Biophys Acta 2013 10.1016/j.bbadis. 2013.07.023
179. T. Nagano, Y. Lubling, T.J. Stevens, S. Schoenfelder, E. Yaffe, and W. Dean et al. Single-cell Hi-C reveals cell-to-cell variability in chromosome structure Nature 502 2013 59 64
180. Estes AC. Chromosomes actually look like an insane ball of Spaghetti; 2013. http://gizmodo.com/chromosomes-actually-look-like-an-insane-ball-of- spaghe-1390765749.
181. T. Misteli Beyond the sequence: cellular organization of genome function Cell 128 2007 787 800 (Pubitemid 46273571)
182. T. Misteli Protein dynamics: implications for nuclear architecture and gene expression Science 291 2001 843 847 (Pubitemid 32120749)
183. T. Cremer, and C. Cremer Chromosome territories, nuclear architecture and gene regulation in mammalian cells Nat Rev Genet 2 2001 292 301 (Pubitemid 33674777)
184. K.L. Reddy, and A.P. Feinberg Higher order chromatin organization in cancer Semin Cancer Biol 23 2013 109 115
185. R. Jones, M. Pembrey, J. Golding, and D. Herrick The search for genenotype/phenotype associations and the phenome scan Paediatr Perinat Epidemiol 19 2005 264 275 (Pubitemid 40897334)
186. J.C. Denny, M.D. Ritchie, M.A. Basford, J.M. Pulley, L. Bastarache, and K. Brown-Gentry et al. PheWAS: demonstrating the feasibility of a phenome-wide scan to discover gene-disease associations Bioinformatics 26 2010 1205 1210
187. S.A. Pendergrass, K. Brown-Gentry, S. Dudek, E.S. Torstenson, J.L. Ambite, and C.L. Avery et al. The use of phenome-wide association studies (PheWAS) for exploration of novel genotype-phenotype relationships and pleiotropy discovery Genet Epidemiol 35 2011 410 422
188. S.J. Hebbring, S.J. Schrodi, Z. Ye, Z. Zhou, D. Page, and M.H. Brilliant A PheWAS approach in studying HLA-DRB1*1501 Genes Immun 14 2013 187 191
189. F.M. Goodsaid, F.W. Frueh, and W. Mattes Strategic paths for biomarker qualification Toxicology 245 2008 219 223
190. I. Gashaw, P. Ellinghaus, A. Sommer, and K. Asadullah What makes a good drug target? Drug Discov Today 16 2011 1037 1043
191. R.M. Plenge, E.M. Scolnick, and D. Altshuler Validating therapeutic targets through human genetics Nat Rev Drug Discov 12 2013 581 594
192. K. Kopec, D.B. Bozyczko-Coyne, and M. Williams Target identification and validation in drug discovery: the role of proteomics Biochem Pharmacol 69 2005 1133 1139 (Pubitemid 40417484)
193. O.K. Sorger, and B. Schoeberl An expanding role for cell biologists in drug discovery and pharmacology Mol Biol Cell 23 2012 4162 4164
194. R.M. Rydzewski Real world drug discovery: a chemist's guide to biotech and pharmaceutical research 2008 Elsevier Oxford, UK 141 143
195. LaMattina J. BCG weighs in on first-in-class vs. best-in-class drugs - how valuable is their advice? Forbes; 2013. http://www.forbes.com/sites/ johnlamattina/2013/06/17/bcg-weighs-in-on-first-in-class-vs-best-in-class-drugs- how-valuable-is-their-advice/.
196. T.Y.-H. Wu, and S. Ding Target validation in chemogenomics B. Metcalf, S. Dillon, Target validation in drug discovery 2007 Academic Press Burlington, MA 27 39
197. M. Grammel, and H.C. Hang Chemical reporters for biological discovery Nat Chem Biol 9 2013 475 484
198. M.E. Bunnage, E.L.P. Chekler, and L.H. Jones Target validation using chemical probes Nat Chem Biol 9 2013 195 199
199. P.H. Hopkins Familial hypercholesterolemia-improving treatment and meeting guidelines Int J Cardiol 89 2003 13 23
200. M. Abifadel, M. Varret, J.-P. Rabès, D. Allard, K. Ouguerram, and M. Devillers et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia Nat Genet 34 2003 154 156 (Pubitemid 36666925)
201. Y. Yang, Y. Wang, S. Li, Z. Xu, H. Li, and L. Ma et al. Mutations in SCN9A, encoding a sodium channel alpha subunit, in patients with primary erythermalgia J Med Genet 41 2004 171 174 (Pubitemid 38333793)
202. J.W. Black Pharmacology: analysis and exploration Brit Med J 293 1986 252 255
203. D.L. Braff Promises, challenges and caveats of translational research in neuropsychiatry J.E. Barrett, J.T. Coyle, M. Williams, Translational neuroscience: applications in neurology, psychiatry, and neurodevelopmental disorders 2012 Cambridge University Press Cambridge, England 352 353
204. T. Kenakin A pharmacology primer: theory, application and methods 3rd ed. 2009 Academic Press Burlington xv
205. J.A. Lee, M.T. Uhlik, C.M. Moxham, D. Tomandl, and D.J. Sall Modern phenotypic drug discovery is a viable, neoclassic pharma strategy J Med Chem 55 2012 4527 4538
206. K.A. Giuliano, R.L. DeBiasio, R.T. Dunlay, A. Gough, J.M. Volosky, and J. Zock et al. High-content screening: a new approach to easing key bottlenecks in the drug discovery process J Biomol Screen 2 1997 249 259 (Pubitemid 127690015)
207. S.J. Enna, and M. Williams Challenges in the search for drugs to treat central nervous system disorders J Pharmacol Exp Ther 329 2009 404 411
208. L. Braff, and D.L. Braff The neuropsychiatric translational revolution: still very early and still very challenging J Am Med Assoc Psychiatry 70 2013 777 779
209. B.L. Roth, D.J. Sheffler, and W.K. Kroeze Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia Nat Rev Drug Discov 3 2004 353 359 (Pubitemid 38499762)
210. R. Morphy, and Z. Rankovic Designed multiple ligands. An emerging drug discovery paradigm J Med Chem 48 2005 6523 6543 (Pubitemid 41504710)
211. M.W. Lochmann van Bennekom, H.J. Gijsman, and F.G. Zitman Antipsychotic polypharmacy in psychotic disorders: a critical review of neurobiology, efficacy, tolerability and cost effectiveness J Psychopharmacol 27 2013 327 336
212. M.C. Genovese Inhibition of p38: has the fat lady sung? Arthritis Rheum 60 2009 317 320
213. T. Maes, G.F. Joos, and G.G. Brusselle Targeting interleukin-4 in asthma: lost in translation? Am J Respir Cell Mol Biol 47 2012 261 270
214. R.J. Hill NK1 (substance P) receptor antagonists -why are they not analgesic in humans? Trends Pharmacol Sci 21 2000 244 246
215. P. Chames, M. Van Regenmortel, E. Weiss, and D. Baty Therapeutic antibodies: successes, limitations and hopes for the future Br J Pharmacol 157 2009 220 233
216. W.J. Groh, M.R. Groh, C. Shen, D.G. Monckton, C.L. Bodkin, and R.M. Pascuzzi Survival and CTG repeat expansion in adults with myotonic dystrophy type 1 Muscle Nerve 43 2011 648 651
217. P.K. Todd, S.Y. Oh, A. Krans, F. He, C. Sellier, and M. Frazer et al. CGG repeat-associated translation mediates neurodegeneration in fragile X tremor ataxia syndrome Neuron 78 2013 440 455
218. J. Jung, M.T.M. van Jaarsveld, S.-Y. Shieh, K. Xu, and N.M. Bonini Defining genetic factors that modulate intergenerational CAG repeat instability in Drosophila melanogaster Genetics 187 2011 61 71
219. W.-Y. Choi, M. Gemberling, J. Wang, J.E. Holdway, M.-C. Shen, and R.O. Karlstrom et al. In vivo monitoring of cardiomyocytes proliferation to identify chemical modifiers of heart regeneration Development 140 2013 660 666
220. J.W.-H. Li, and J.C. Vederas Drug discovery and natural products: end of an era or an endless frontier? Science 325 2009 161 165
221. F. Yu, T. Takahashi, J. Moriya, K. Kawaura, J. Yamakawa, and K. Kusaka et al. Traditional Chinese medicine and Kampo: a review from the distant past for the future J Int Med Res 34 2006 231 239 (Pubitemid 44057265)
222. R. Verpoorte, D. Crommelin, M. Danhof, L.J.W.J. Gilissen, H. Schuitmaker, and J. van der Greef et al. Commentary: "a systems view on the future of medicine: inspiration from Chinese medicine? J Ethnopharmacol 121 2009 479 481
223. J. van der Greef, H. van Wietmarschen, J. Schroro, M. Wang, T. Hankemeier, and G. Xu Systems biology-based diagnostic principles as pillars of the bridge between Chinese and western medicine Planta Med 76 2010 2036 2047
224. D.J. Newman, and G.M. Cragg Natural products as sources of new drugs over the 30 years from 1981 to 2010 J Nat Prod 75 2012 311 335
225. S. Bent, C. Kane, K. Shinohara, J. Neuhaus, E.S. Hudes, and H. Goldberg et al. Saw palmetto for benign prostatic hyperplasia N Engl J Med 354 2006 557 566 (Pubitemid 43209103)
226. C. Randløv, J. Mehlsen, C.F. Thomsen, C. Hedman, H. von Fircks, and Wintherk The efficacy of St. John's Wort in patients with minor depressive symptoms or dysthymia - a double-blind placebo-controlled study Phytomedicine 13 2006 215 221 (Pubitemid 43255319)
227. L.M. Howells, E.P. Moiseeva, C.P. Neal, B.E. Foreman, C.K. Andreadi, and Y.-Y. Sun et al. Predicting the physiological relevance of in vitro cancer preventive activities of phytochemicals Acta Pharmacol Sin 28 2007 1274 1304 (Pubitemid 47366687)
228. B.B. Aggarwal, and B. Sung Pharmacological basis for the role of curcumin in chronic diseases: an age-old spice with modern targets Trends Pharmacol Sci 30 2009 85 94
229. C.A. Lipinski, F. Lombardo, B.W. Dominy, and P.J. Feeney Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings Adv Drug Deliv Rev 46 2001 3 26 (Pubitemid 33653411)
230. M.S. Butler The role of natural product chemistry in drug discovery J Nat Prod 64 2004 2141 2153 (Pubitemid 40092578)
231. J. Clardy, M.A. Fischbach, and C.T. Walsh New antibiotics from bacterial natural products Nat Biotechnol 24 2006 1541 1550 (Pubitemid 44967478)
232. C.J. Henrich, and J.A. Beutler Matching the power of high throughput screening to the chemical diversity of natural products Nat Prod Rep 30 2013 1284 1298
233. P. Pound, S. Ebrahim, P. Sandercock, M.B. Bracken, and I. Roberts Where is the evidence that animal research benefits humans? Br Med J 328 2004 514 517 (Pubitemid 38293622)
234. M.B. Bracken Why animal studies are often poor predictors of human reactions to exposure J R Soc Med 102 2009 120 122
235. H.B. van der Worp, D.W. Howells, E.S. Sena, M.J. Porritt, S. Rewell, and V. O'Collins et al. Can animal models of disease reliably inform human studies? PLoS Med 7 2010 e1000245
236. D.R. Webb Animal models of human disease: inflammation Biochem Pharm 87 2014 121 130
237. K. Mullane, and M. Williams Animal models of asthma: reprise or reboot? Biochem Pharm 87 2014 131 139
238. B.A. Ruggeri, F. Camp, and S. Miknyoczki Animal models of disease: pre-clinical animal models of cancer and their applications and utility in drug discovery Biochem Pharm 87 2014 150 161
239. P. McGonigle Animal models of CNS disorders Biochem Pharm 87 2014 140 149
240. J. Higgins, M.E. Cartwright, and A.C. Templeton Progressing preclinical drug candidates: strategies on preclinical safety studies and the quest for adequate exposure Drug Discov Today 17 2012 828 836
241. J. Gabrielsson, H. Dolgos, P.-G. Gillberg, U. Bredberg, B. Benthem, and G. Duker Early integration of pharmacokinetic and dynamic reasoning is essential for optimal development of lead compounds: strategic considerations Drug Disc Today 14 2009 358 372
242. T. Bueters, B.A. Ploeger, and S.A.G. Visser The virtue of translational PKPD modeling in drug discovery: selecting the right clinical candidate while sparing animal lives Drug Discov Today 8 2013 853 862
243. S. Goineau, M. Lemaire, and G. Froget Overview of safety pharmacology Curr Protoc Pharmacol 2013 10.1.1 10.1.8
244. P. Perel, I. Roberts, E. Sena, P. Wheble, C. Briscoe, and P. Sandercock et al. Comparison of treatment effects between animal experiments and clinical trials: systematic review Br Med J 334 2007 197
245. H.B. Van der Worp, and J. Van Gijn Clinical practice. Acute ischemic stroke N Engl J Med 57 2007 572 579 (Pubitemid 47236282)
246. V.E. O'Collins, M.R. Macleod, G.A. Donnan, L.L. Horky, B.H. van der Worp, and D.W. Howells 1,026 experimental treatments in acute stroke Ann Neurol 59 2006 467 477 (Pubitemid 43358067)
247. M.R. Macleod, H.B. van der Worp, E.S. Sena, D.W. Howells, U. Dirnagl, and U. Dirnagl et al. Evidence for the efficacy of NXY-059 in experimental focal cerebral ischaemia is confounded by study quality Stroke 39 2008 2824 2829
248. M.R. Macleod, M. Fisher, V. O'Collins, E.S. Sena, U. Dirnagl, and P.M.W. Bath et al. Reprint: good laboratory practice: preventing introduction of bias at the bench J Cerebral Blood Flow Metab 29 2009 221 223
249. P.M.W. Bath, L.J. Gray, A.J.G. Bath, A. Buchan, T. Miyata, and A.R. Green et al. Effects of NCY-059 in experimental stroke: an individual animal meta-analysis Br J Pharmacol 157 2009 1157 1171
250. E.S. Sena, H.B. van der Worp, P.M.W. Bath, D.W. Howells, and M.R. Macleod Publication bias in reports of animal stroke studies leads to major overstatement of efficacy PLoS Biol 8 2010 e1000344
251. M. von Herrath, and G.T. Nepom Animal models of human type 1 diabetes Nat Immunol 10 2009 129 132
252. M. Jucker The benefits and limitations of animal models for translational research in neurodegenerative diseases Nat Med 16 2010 1210 1214
253. J. Seok, H.S. Warren, A.G. Cuenca, M.N. Mindrinos, H.V. Baker, and W. Xu et al. Genomic responses in mouse models poorly mimic human inflammatory diseases Proc Natl Acad Sci USA 110 2013 3507 3512
254. M. Williams, and S.J. Enna Defining the role of pharmacology in the emerging world of translational research Adv Pharmacol 57 2009 1 30
255. J. Le Fanu The rise and fall of modern medicine 2nd ed. 2011 Abacaus London 300 306
256. D.F. Klein The loss of serendipity in psychopharmacology J Am Med Assoc 299 2008 1063 1065 (Pubitemid 351347065)
257. J.P. Ioannidis Extrapolating from animals to humans Sci Transl Med 4 2012 151ps115
258. H.B. Van der Worp, D.W. Howells, E.S. Sena, M.J. Porritt, S. Rewell, and V. O'Collins et al. Can animal studies of disease reliably inform human studies? PLoS Med 7 2010 e1000245
259. S.C. Landis, S.G. Amara, K. Asadullah, C.P. Austin, R. Blumenstein, and E.W. Bradley et al. A call for transparent reporting to optimize the predictive value of preclinical research Nature 490 2012 187 191
260. C.R. Hooijmans, and M. Ritskes-Hoitinga Progress in using systematic reviews of animal studies to improve translational research PLoS Med 10 2013 e1001482
261. H.H. Heng HeLa genome versus donor's genome Nature 501 2013 167
262. J.P. Gillet, A.M. Calcagno, S. Varma, M. Marino, L.J. Green, and M.I. Vora et al. Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance Proc Natl Acad Sci USA 108 2011 18708 18713
263. S. Yamanaka Induced pluripotent stem cells: past, present, and future Cell Stem Cell 10 2012 678 688
264. F.T. Merkle, and K. Eggan Modeling human disease with pluripotent stem cells: from genome association to function Cell Stem Cell 12 2013 656 668
265. M. Bellin, M.C. Marchetto, F.H. Gage, and C. Mummery Induced pluripotent stem cells: the new patient? Nat Rev Mol Cell Biol 13 2012 713 726
266. M.C. Puri, and A. Nagy Concise review: embryonic stem cells versus induced pluripotent stem cells: the game is on Stem Cells 30 2012 10 14
267. Q. Ding, Y.-K. Lee, E.A.K. Schaefer, D.T. Peters, and A. Veres et al. A TALEN genome-editing system for generating human stem cell-based disease models Cell Stem Cell 12 2013 238 251
268. R.M. Walsh, and K. Hochedlinger A variant CRISPR-Cas9 system adds versatility to genome engineering Proc Natl Acad Sci USA 110 2013 15514 15515
269. C. Kim, J. Wong, J. Wen, S. Wang, C. Wang, and S. Spiering et al. Studying arrhythmogenic right ventricular dysplasia with patient-specific iPSCs Nature 494 2001 105 110
270. A.L. Lahti, V.J. Kujala, H. Chapman, A.-P. Koivisto, M. Pekkanen-Mattila, and E. Kirkela et al. Model for long QT syndrome type 2 using human iPS cells demonstrates arrhythmogenic characteristics in cell culture Dis Models Mech 5 2012 220 230
271. K.R. Chi Revolution dawning in cardiotoxicity testing Nat Rev Dug Discov 12 2013 565 567
272. J.A. Kaye, and S. Finkbeiner Modeling Huntington's disease with induced pluripotent stem cells Mol Cell Neurosci 56 2013 50 64
273. J. Drouin-Ouellet, and R.A. Barker Parkinson's disease in a dish: what patient specific-reprogrammed somatic cells can tell us about Parkinson's disease, if anything? Stem Cells Int 2012 2012 926147
274. P. Reinhardt, B. Schmid, L.F. Burbulla, D.C. Schöndorf, L. Wagner, and M. Glatza et al. Genetic correction of a LRRK2 mutation in human iPSCs links parkinsonian neurodegeneration to ERK-dependent changes in gene expression Cell Stem Cell 12 2013 354 367
275. G. Lee, C.N. Ramirez, H. Kim, N. Zeltner, B. Liu, and C. Radu Large-scale screening using familial dysautonomia induced pluripotent stem cells identifies compounds that rescue IKBKAP expression Nat Biotechnol 30 2012 1244 1248
276. D.G. Flood, G.J. Marek, and M. Williams Developing predictive CSF biomarkers -a challenge critical to success in Alzheimer's disease and neuropsychiatric translational medicine Biochem Pharmacol 81 2011 1422 1434
277. J. Talpos Steckler touching on translation Cell Tissue Res 2013 10.1007/s00441-013-1694-7
278. M. Wehling Translational medicine: can it really facilitate the transition of research 'from bench to bedside'? Eur J Clin Pharmacol 62 2006 91 95
279. M. Wehling Drug development in the light of translational science: shine or shade? Drug Discov Today 16 2011 1076 1083
280. M. Wehling Assessing the translatability of drug projects: what needs to be scored to predict success? Nat Rev Drug Discov 8 2009 541 546
281. P.L. LoRusso Phase 0 clinical trials: an answer to drug development stagnation? J Clin Oncol 27 2009 2586 2588
282. Z. Zetterberg, N. Mattsson, K. Blennow, and B. Olsson Use of theragnostic markers to select drugs for phase II/III trials for Alzheimer disease Alzheimer's Res Ther 2 2010 32
283. G. De Meyer, F. Shapiro, H. Vanderstichele, E. Vanmechelen, S. Engelborghs, and P.P. De Deyn et al. Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly people Arch Neurol 67 2010 949 956
284. CMS. Decision memo for beta amyloid positron emission tomography in dementia and neurodegenerative disease (CAG-00431N); 2013. http://www.cms.gov/ medicare-coverage-database/details/nca-decision-memo.aspx?NCAId= 265&utm-medium=email&utm-source=govdelivery.
285. A. Wendler, and M. Wehling Translatability scoring in drug development: eight case studies J Transl Med 10 2012 39
286. R. Féliste, D. Delebassée, M.F. Simon, H. Chap, G. Defreyn, and E. Vallée et al. Broad spectrum anti-platelet activity of ticlopidine and PCR 4099 involves the suppression of the effects of released ADP Thromb Res 48 1987 403 415
287. D.J. Fitzgerald, and G.A. FitzGerald Historical lessons in translational medicine: cyclooxygenase inhibition and P2Y12 Antagonism Circ Res 112 2013 174 194
288. G. Hollopeter, H.M. Jantzen, D. Vincent, G. Li, L. England, and V. Ramakrishnan et al. Identification of the platelet ADP receptor targeted by antithrombotic drugs Nature 409 2001 202 207 (Pubitemid 32144286)
289. A. Shuaib, K.R. Lees, P. Lyden, J. Grotta, A. Davalos, and S.M. Davis et al. NXY-059 for the treatment of acute ischemic stroke N Engl J Med 357 2007 562 571 (Pubitemid 47236281)
290. H.C. Diener, K.R. Lees, P. Lyden, J. Grotta, A. Davalos, and S.M. Davis et al. NXY-059 for the treatment of stroke: pooled analysis of the SAINT I and II trials Stroke 39 2008 1571 1578
291. E. van de Steeg, R. Kleemann, H.T. Jansen, W. van Duyvenvoorde, E.H. Offerman, and H.M. Wortelboer et al. Combined analysis of pharmacokinetic and efficacy data of preclincal studies with statins markedly improves translation of drug efficacy to human trials J Pharmacol Exp Ther 2013 10.1124/jpet.113. 208595
292. Goodman L. Norbeck T. Who's to blame for our rising healthcare costs? Forbes; 2013. http://www.forbes.com/sites/physiciansfoundation/2013/10/03/whos- to-blame-for-our-rising-healthcare-costs/.
293. Booth B. Academic bias & biotech failures Life SciVC; 2011. http://lifescivc.com/2011/03/academic-bias-biotech-failures/.
294. J.C.M. Uitdehaag The seven types of drug discovery waste: toward a new lean for the drug industry Drug Discov Today 16 2011 369 371
295. P.G. Germann, A. Schuhmacher, J. Harrison, R. Law, K. Haug, and G. Wong How to create innovation by building the translation bridge from basic research into medicinal drugs: an industrial perspective Hum Genome 7 2013 5
296. F.C. Fang, and A. Casadevall Lost in translation - basic science in the era of translational research Infect Immun 78 2010 563 566
297. A. Casadevall, and F.C. Fang Reforming science: methodological and cultural reforms Infect Immun 80 2012 891 896
298. F.C. Fang, and A. Casadevall Reforming science: structural reforms Infect Immun 80 2012 897 901